Loading...
XMAD
CBAV
Market cap1.01bUSD
Jun 18, Last price  
55.00EUR
1D
-1.08%
1Q
10.89%
Jan 2017
478.95%
IPO
134.04%
Name

Clinica Baviera SA

Chart & Performance

D1W1MN
XMAD:CBAV chart
P/E
21.92
P/S
3.36
EPS
2.51
Div Yield, %
2.85%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
16.13%
Revenues
263m
+16.77%
43,396,64763,527,04278,381,63287,936,70783,141,22489,682,81493,592,99989,880,51979,975,65082,620,56385,527,35291,572,17699,879,659109,293,546124,333,421122,625,591172,730,250198,449,250224,923,951262,648,000
Net income
40m
+11.77%
9,378,896-26,285,570-23,666,4287,011,5781,860,8355,239,0395,403,828-87,5874,886,6494,054,8894,879,7167,914,4209,770,09611,826,23712,794,64713,941,69727,389,52729,518,52835,970,92840,205,000
CFO
63m
+8.56%
015,753,36419,538,92610,262,7058,106,31114,445,15614,526,8938,086,34210,221,3899,664,72610,838,74413,545,58415,831,36416,813,73225,402,08631,455,53046,856,58853,377,07257,812,11562,762,000
Dividend
Jun 11, 20251.57 EUR/sh
Earnings
Jul 20, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditions. Its facilities offer a wide range of specialized services, addressing issues such as myopia, hyperopia, astigmatism, presbyopia, cataracts, retinal disorders, pediatric eye ailments, glaucoma, strabismus (squint), corneal diseases, neuro-ophthalmology, lacrimal duct problems (vías lagrimales), and oculoplastic procedures. Operating around 90 sites, the company's geographical footprint extends across Spain, Germany, Austria, and Italy. The corporate headquarters are located in Madrid, Spain.
IPO date
Jan 01, 2000
Employees
1,423
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT